Mesenchymal Stromal Cells in Knee Osteoarthritis: A Review of Nomenclature, Criteria, and Therapeutic Mechanisms

Doo-Ho Lim,1,* Chae-Chil Lee,2,* Ki-Bong Park2 1Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea; 2Department of Orthopedic Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea*These authors contributed equally to this workCorrespondence: Ki-Bong Park, Department of Orthopedic Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Dong-Gu, Ulsan, Republic of Korea, Tel +82 52 250 7129, Fax +82 52 235 2823, Email [email protected]: Cell-based therapies, particularly utilizing mesenchymal cells, have garnered significant global attention for treating knee osteoarthritis (OA). However, interpreting clinical outcomes remains challenging due to substantial heterogeneity in study designs, cell sources, and preparation methods. This narrative review aims to clarify the evolving nomenclature, outline defining criteria, and elucidate the fundamental mechanisms of these therapies. We highlight the critical scientific transition from “mesenchymal stem cells” to “mesenchymal stromal cells”, an adjustment strongly supported by recent clinical approvals emphasizing immune recalibration over direct tissue regeneration. Currently, robust evidence indicates that mesenchymal stromal cells exert their therapeutic effects primarily through paracrine signaling and immunomodulation, predominantly orchestrated by exosomes, rather than through lineage-driven direct structural repair. Furthermore, we address the practical implications of cell processing—differentiating between minimal manipulation (e.g. cell concentrates) and in vitro expansion—and the stringent regulatory frameworks governing them. Ultimately, standardizing the mechanism-accurate “stromal” terminology and optimizing cell preparation protocols are essential steps for advancing the efficacy and reliability of regenerative treatments in knee OA.Keywords: osteoarthritis, knee, mesenchymal stem cells, exosomes, paracrine communication, regenerative medicine, cell- and tissue-based therapy

Authors

Publication Details

Journal
Therapeutics and Clinical Risk Management
Published
2026-05-01
DOI
https://doi.org/10.2147/tcrm.s594869
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mesenchymal Stromal Cells in Knee Osteoarthritis: A Review of Nomenclature, Criteria, and Therapeutic Mechanisms

Doo‐Ho Lim, Chae-Chil Lee, Ki-Bong Park
Therapeutics and Clinical Risk Management
Mesenchymal stem cell research
article

Mesenchymal Stromal Cells in Knee Osteoarthritis: A Review of Nomenclature, Criteria, and Therapeutic Mechanisms

Doo‐Ho Lim, Chae-Chil Lee, Ki-Bong Park
article en

Abstract

Doo-Ho Lim,1,* Chae-Chil Lee,2,* Ki-Bong Park2 1Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea; 2Department of Orthopedic Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea*These authors contributed equally to this workCorrespondence: Ki-Bong Park, Department of Orthopedic Surgery, Ulsan University Hospital, University of Ulsan College of Medicine, Dong-Gu, Ulsan, Republic of Korea, Tel +82 52 250 7129, Fax +82 52 235 2823, Email [email protected]: Cell-based therapies, particularly utilizing mesenchymal cells, have garnered significant global attention for treating knee osteoarthritis (OA). However, interpreting clinical outcomes remains challenging due to substantial heterogeneity in study designs, cell sources, and preparation methods. This narrative review aims to clarify the evolving nomenclature, outline defining criteria, and elucidate the fundamental mechanisms of these therapies. We highlight the critical scientific transition from “mesenchymal stem cells” to “mesenchymal stromal cells”, an adjustment strongly supported by recent clinical approvals emphasizing immune recalibration over direct tissue regeneration. Currently, robust evidence indicates that mesenchymal stromal cells exert their therapeutic effects primarily through paracrine signaling and immunomodulation, predominantly orchestrated by exosomes, rather than through lineage-driven direct structural repair. Furthermore, we address the practical implications of cell processing—differentiating between minimal manipulation (e.g. cell concentrates) and in vitro expansion—and the stringent regulatory frameworks governing them. Ultimately, standardizing the mechanism-accurate “stromal” terminology and optimizing cell preparation protocols are essential steps for advancing the efficacy and reliability of regenerative treatments in knee OA.Keywords: osteoarthritis, knee, mesenchymal stem cells, exosomes, paracrine communication, regenerative medicine, cell- and tissue-based therapy

Therapeutics and Clinical Risk ManagementVol. Volume 22
Good health and well-being
Openalex Percentile: Top 8%
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.